Diagnostic marker for type 1 diabetes mellitus
View Patent ↗The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.
1. A method for diagnosing type 1 diabetes mellitus comprising:
obtaining a sample from a subject suspected of having type 1 diabetes mellitus;
contacting the sample with two or more purified recombinant proteins selected from the group consisting of alanyl tRNA synthetase, glycyl tRNA synthetase, asparaginyl tRNA synthetase, and tryptophanyl tRNA synthetase, and fragments thereof;
detecting the binding of two or more of an anti-alanyl tRNA synthetase antibody, an anti-glycyl tRNA synthetase antibody, an anti-asparaginyl tRNA synthetase antibody, and an anti-tryptophanyl tRNA synthetase antibody in the sample with the two or more purified recombinant proteins,
wherein detecting the binding of two or more of the antibodies with the two or more purified recombinant proteins indicates that the subject has type 1 diabetes mellitus.
2. The method of claim 1 , further comprising a step of:
detecting a marker for diagnosis of type 1 diabetes mellitus selected from the group consisting of anti-Glutamate decarboxylase 65 (GAD65) antibody, anti-islet antigen-2 (IA-2) antibody, anti-insulin antibody, anti-islet-cell antigen (ICA) antibody, hemoglobin A1C (HbA1C) level, C-peptide level, and Solute Carrier Family 30-Member 8 (Slc30A8) level in the sample obtained from the subject.
3. A method for diagnosing type 1 diabetes mellitus consisting of:
obtaining a sample from a subject suspected of having type 1 diabetes mellitus;
contacting the sample with two or more purified recombinant proteins selected from the group consisting of alanyl tRNA synthetase, glycyl tRNA synthetase, asparaginyl tRNA synthetase, and tryptophanyl tRNA synthetase, and fragments thereof;
detecting the binding of two or more of an anti-alanyl tRNA synthetase antibody, an anti-glycyl tRNA synthetase antibody, an anti-asparaginyl tRNA synthetase antibody, and an ant-tryptophanyl tRNA synthetase antibody in the sample with the two or more purified recombinant proteins,
wherein detecting the binding of two or more of the antibodies with the two or more purified recombinant proteins indicates that the subject has type 1 diabetes mellitus.
4. A method for diagnosing type 1 diabetes mellitus consisting of:
obtaining a sample from a subject suspected of having type 1 diabetes mellitus;
contacting the sample with two or more purified recombinant proteins selected from the group consisting of alanyl tRNA synthetase, glycyl tRNA synthetase, asparaginyl tRNA synthetase, and tryptophanyl tRNA synthetase, and fragments thereof;
detecting the binding of two or more of an anti-alanyl tRNA synthetase antibody, an anti-glycyl tRNA synthetase antibody, an anti-asparaginyl tRNA synthetase antibody, and an anti-tryptophanyl tRNA synthetase antibody in the sample with the two or more purified recombinant proteins;
detecting a marker for diagnosis of type 1 diabetes mellitus selected from the group consisting of anti-Glutamate decarboxylase 65 (GAD65) antibody, anti-islet antigen-2 (IA-2) antibody, anti-insulin antibody, anti-islet-cell antigen (ICA) antibody, hemoglobin A1C (HbA1C) level, C-peptide level, and Solute Carrier Family 30-Member 8 (Slc30A8) level in the sample;
wherein detecting the binding of two or more of the antibodies with the two or more purified recombinant proteins and the presence of the marker for diagnosis of type 1 diabetes mellitus in the sample indicates that the subject has type 1 diabetes mellitus.